Israel Englander’s KalVista Pharmaceuticals KALV Stock Holding History

Israel Englander’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,500	Closed	-$380K	–	6045
2025 Q4	$380K	Buy	23,500 +3,500	+18%	+$46.4K	﹤0.01%	5119
2025 Q3	$244K	Buy	+20,000	New	+$276K	﹤0.01%	5451
2023 Q3	–	Sell	-50,000	Closed	-$450K	–	6345
2023 Q2	$450K	Buy	+50,000	New	+$461K	﹤0.01%	4614
2023 Q1	–	Sell	-100,000	Closed	-$676K	–	6608
2022 Q4	$676K	Buy	+100,000	New	+$536K	﹤0.01%	4508

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Israel Englander's KALV Position: Q2 2026 in Review

Israel Englander sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,912,146 shares — an estimated $38.5M sold.

Israel Englander first reported a position in KALV in Q2 2016 and held it in 25 quarters. The position peaked at $46.8M in Q4 2025. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Israel Englander reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 1,912,146 KalVista Pharmaceuticals shares in Q2 2026, an estimated $38.5M.
Israel Englander first reported a position in KalVista Pharmaceuticals in Q2 2016 and held it in 25 quarters.
Israel Englander's KalVista Pharmaceuticals position peaked at $46.8M in Q4 2025.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.